A carregar...

Evaluating immune responses after sipuleucel-T therapy

Following FDA approval of sipuleucel-T in 2010 for metastatic castration resistant prostate cancer (mCRPC), several studies have described the effect of sipuleucel-T on peripheral immune responses. Retrospective associations have also been made with immune responses and survival. A recently publishe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Strauss, Julius, Madan, Ravi A, Figg, William D
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622939/
https://ncbi.nlm.nih.gov/pubmed/26054644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1056417
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!